Cytosorbents (CTSO) Expected to Post Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Cytosorbents to post earnings of ($0.05) per share and revenue of $9.3850 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Cytosorbents had a negative return on equity of 235.57% and a negative net margin of 31.85%.The business had revenue of $8.86 million during the quarter, compared to the consensus estimate of $9.40 million. On average, analysts expect Cytosorbents to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Price Performance

NASDAQ CTSO opened at $0.37 on Tuesday. Cytosorbents has a fifty-two week low of $0.35 and a fifty-two week high of $1.22. The stock’s 50-day moving average is $0.41 and its two-hundred day moving average is $0.56. The firm has a market cap of $23.13 million, a P/E ratio of -1.94 and a beta of 1.39. The company has a debt-to-equity ratio of 4.70, a current ratio of 1.09 and a quick ratio of 0.81.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research report on Monday, July 6th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.38.

Insider Buying and Selling at Cytosorbents

In other news, CEO Phillip P. Chan bought 251,136 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average cost of $0.40 per share, for a total transaction of $100,454.40. Following the completion of the purchase, the chief executive officer owned 1,734,099 shares of the company’s stock, valued at $693,639.60. This trade represents a 16.93% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Cytosorbents

Institutional investors and hedge funds have recently bought and sold shares of the business. CIBC Bancorp USA Inc. acquired a new position in Cytosorbents in the third quarter valued at about $161,000. Avenir Corp increased its holdings in shares of Cytosorbents by 2.9% during the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after buying an additional 147,261 shares in the last quarter. Vanguard Group Inc. grew its position in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.